Publication: Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status
Issued Date
2009-01-01
Resource Type
ISSN
17341140
Other identifier(s)
2-s2.0-70549110067
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmacological Reports. Vol.61, No.5 (2009), 892-898
Suggested Citation
Amar Nagila, Thinnakorn Permpongpaiboon, Soontharee Tantrarongroj, Pornwalee Porapakkham, Kultira Chinwattana, Sara Deakin, Sureerut Porntadavity Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacological Reports. Vol.61, No.5 (2009), 892-898. doi:10.1016/S1734-1140(09)70146-X Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/28335
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status
Abstract
It has been proposed that paraoxonasel (PON1), a high density lipoprotein (HDL)-associated esterase/lactonase, has antiatherosclerotic properties. The activity of PON1 is influenced by PON1 polymorphisms. However, the influence of PON1 polymorphisms on PON1 activity and oxidative stress in response to lipid-lowering drugs remains poorly understood. The objective of the present study was to investigate the effects of atorvastatin on PON1 activity and oxidative status. The influence of PON1 polymorphisms on PON1 activity and oxidative status in response to atorvastatin treatment was also evaluated. In total, 22 hypercholesterolemic patients were treated with atorvastatin at a dose of 10 mg/day for 3 months. Lipid profile, lipid oxidation markers (malondialdehyde (MDA), conjugated diene (CD), total peroxides (TP)), total antioxidant substance (TAS), oxidative stress index (OSI), and paraoxonasel activity were determined before and after treatment. L55M, Q192R, and T(-107)C PON1 polymorphisms were also determined. Atorvastatin treatment significantly reduced the levels of total cholesterol (24.5%), low density lipoprotein (LDL) cholesterol (25.4%), triglycerides (24.4%), CD (4.4%), MDA (15.2%), TP (13.0%) and OSI (24.0%), and significantly increased the levels of TAS (27.3%), and PON1 activity (14.0%). Interestingly, the increase in PON1 activity and the reduction in oxidative stress in response to atorvastatin were influenced only by the PON1 T-107C polymorphism. Atorvastatin treatment improved the lipid profile, lipid oxidation, and oxidative/antioxidative status markers including the activity of PON1 towards paraoxon. These beneficial effects may be attributed to the antioxidant properties of statins and the increase in PON1 activity. The increase in PON1 activity was enhanced by the PON1 T-107C polymorphism. Copyright © 2009 by Institute of Pharmacology Polish Academy of Sciences.